Mycenax Biotech Inc.

EN

Please enter the company code as 4726 http://emops.twse.com.tw/server-java/t58query Go to Link
Milestones Milestones
  • 2018

    Oct

    Business of CDMO services expands to Korea market.

    Jan

    TuNEX(ENIA11) gets approval for the first new biological entity market authorization from TFDA.

  • 2017

    May

    Fill/Finishing line was upgraded, and increased a new container cartridge aseptic line. Business of CDMO services expands to China market.

    Mar

    Business of CDMO services expands to the US market.

  • 2016

    Nov

    Mycenax in-house MBICHO medium has been innovated for improving the competitive capacity of CDMO services.

    Sep

    The third manufacturing line started to construct.

  • 2015

    Jun

    Mycenax signed an agreement of contract manufacturing biologics with an Australian biopharma. Business of CDMO services expands to Australia market.

  • 2014

    Dec

    Development project of LusiNEX received grants from MEA.

    Oct

    Mycenax signed an agreement of contract manufacturing biologics with Japanese biopharma. CDMO services expand to Japan market.

    Apr

    Completed construction of 2000L bioreactor as the first in Taiwan.。

  • 2013

    Dec

    Mycenax Cooperate stock was officially listed on Stock Exchange at Dec. 25, 2013.

    Nov

    Mycenax began the development project of LusiNEX.

    Oct

    Mycenax received PIC/S GMP certificate from TFDA.

    Sep

    TuNEX received a silver award of Pharmaceutical Technology Research and Development Award from TFDA.

    Mar

    Mycenax signed an agreement of contract manufacturing biologics with European biopharma. CDMO services expanded to the EU market.

  • 2012

    Dec

    Mycenax partnered with TSH Biopharm, for TSH to be responsible for phase III clinical trial and NDA submission, and Myce

  • 2011

    Dec

    TFDA approved phase III clinical trial of TuNEX in Taiwan.

  • 2009

    Oct

    TuNEX received approval to enter phase III clinical trial from Korea FDA.

  • 2008

    Nov

    Mycenax received a bronze award of Taiwan Biotech industry Awards.

    Oct

    Mycenax was registered as the listed company at the emerging stock market. Mycenax was categorized formally as biopharmaceutical company by MEA.

    Aug

    Started to conduct the second tier of MEA Industrial TDP, from Aug. 2008 -

  • 2007

    Nov

    TuNEX was approved to enter phase I/II clinical trial.

    Apr

    The development project of GranNEX started to conduct and was supported by MEA Industrial TDP.

  • 2006

    Apr

    Issued the IPO (4726).

  • 2005

    Aug

    Mycenax conducted Follow-on Biologics project granted by MEA for TuNEX pre-clinical development from Aug. 2005 to Jul. 2

    Jan

    Registered DMF to FDA (DMF no.17981)

  • 2003

    Oct

    Completed construction of biologics plant in Jhunan Science Park.

  • 2002

    May

    Established and installed in Jhunan Science Park.

  • 2001

    Sep

    Myceanx was established in Xindian Dist., New Taipei City.